Skip to main content
ACOG
NASDAQ Life Sciences

Alpha Cognition Appoints Experienced Biopharma CFO Bethany Sensenig to Board of Directors

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$6.89
Mkt Cap
$150.024M
52W Low
$3.97
52W High
$11.54
52W Position info
74% above low
Off High info
40% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

ACOG sits 74% above its 52-week low of $3.97.

Summary

Alpha Cognition Inc. appointed Bethany Sensenig, a seasoned biopharmaceutical CFO and operations executive, to its Board of Directors, enhancing the board's financial and strategic expertise.


Key Events · Executive and Board Changes · ACOG

  • New Director Appointed

    Bethany Sensenig, an experienced biopharmaceutical executive, was appointed to the Board of Directors on April 15, 2026.

  • Extensive Financial & Operational Background

    Ms. Sensenig previously served as CFO and Head of Operations at Radius Health, Inc., CFO and Interim CEO at 9 Meters Biopharma, and held senior finance and commercial operations roles at Biogen Inc., bringing significant expertise in growth, financial performance, and M&A.

  • Standard Director Compensation

    In connection with her appointment, Ms. Sensenig received an initial grant of 5,489 restricted stock units and 6,991 stock options with an exercise price of $6.65 per share, both vesting one year after the grant date.


Analysis · ACOG · Life Sciences

Alpha Cognition Inc. has strengthened its board with the appointment of Bethany Sensenig, a highly experienced biopharmaceutical executive. Her background as CFO and Head of Operations at commercial-stage companies like Radius Health, Inc., and her extensive tenure at Biogen Inc., brings critical financial and operational expertise. This appointment is a positive development for corporate governance and strategic oversight, especially following the company's recent 2025 annual report which disclosed a material weakness and increased cash burn. Her experience in growth, financial performance, and M&A could be instrumental in guiding the company's future.

At the time of this filing, ACOG was trading at $6.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $150M. The 52-week trading range was $3.97 to $11.54. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ACOG - Latest Insights

ACOG
Jul 29, 2026, 8:30 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $8.75
Real-time Price: $8.67 info
Change: -$0.085 (-0.97%) info
Market Cap: $188.673M info
ACOG
Jul 24, 2026, 4:05 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $7.90
Real-time Price: $8.67 info
Change: +$0.765 (+10%) info
Market Cap: $188.673M info
ACOG
Jun 29, 2026, 4:05 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $6.81
Real-time Price: $8.67 info
Change: +$1.85 (+27%) info
Market Cap: $188.673M info
ACOG
Jun 09, 2026, 8:01 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $6.40
Real-time Price: $8.67 info
Change: +$2.26 (+35%) info
Market Cap: $188.673M info
ACOG
May 14, 2026, 4:15 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $5.68
Real-time Price: $8.67 info
Change: +$2.98 (+53%) info
Market Cap: $188.673M info